Search research articles
Contact Us
Filters
Showing results (171-180 of 289) with videos related to
Page
of 29
Sort By:
World Journal of Clinical Oncology
|
December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Sebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Journal of Translational Medicine
|
February 4, 2023
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, et al.
Therapeutic Advances in Medical Oncology
|
March 10, 2023
Clinical outcomes of volume of disease on patients receiving enzalutamide <i>versus</i> abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, et al.
Therapeutic Advances in Medical Oncology
|
January 24, 2024
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)
Pierangela Sepe, Giuseppe Procopio, Chiara Carlotta Pircher, et al.
Tumori
|
May 4, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma
Alessandro Rametta, Sebastiano Buti, Marco Stellato, et al.
JAMA Network Open
|
October 14, 2021
Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial
Caterina Caminiti, Maria Antonietta Annunziata, Claudio Verusio, et al.
European Urology Oncology
|
January 31, 2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, et al.
Frontiers in Oncology
|
November 17, 2022
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
Cora N Sternberg, Nara Shin, Konstantin Chernyshov, et al.
Diagnostics (Basel, Switzerland)
|
January 22, 2021
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Future Oncology (London, England)
|
September 13, 2018
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program
Francesca Maines, Ugo De Giorgi, Giuseppe Procopio, et al.
Page
of 29
Search research articles
Search
Showing results (171-180 of 289) with videos related to
Sort By:
Page
of 29
World Journal of Clinical Oncology
|
December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Sebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Journal of Translational Medicine
|
February 4, 2023
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, et al.
Therapeutic Advances in Medical Oncology
|
March 10, 2023
Clinical outcomes of volume of disease on patients receiving enzalutamide <i>versus</i> abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, et al.
Therapeutic Advances in Medical Oncology
|
January 24, 2024
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)
Pierangela Sepe, Giuseppe Procopio, Chiara Carlotta Pircher, et al.
Tumori
|
May 4, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma
Alessandro Rametta, Sebastiano Buti, Marco Stellato, et al.
JAMA Network Open
|
October 14, 2021
Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial
Caterina Caminiti, Maria Antonietta Annunziata, Claudio Verusio, et al.
European Urology Oncology
|
January 31, 2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, et al.
Frontiers in Oncology
|
November 17, 2022
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
Cora N Sternberg, Nara Shin, Konstantin Chernyshov, et al.
Diagnostics (Basel, Switzerland)
|
January 22, 2021
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Future Oncology (London, England)
|
September 13, 2018
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program
Francesca Maines, Ugo De Giorgi, Giuseppe Procopio, et al.
Page
of 29